GNPX Genprex Inc.

1.86
+0.07  (+4%)
Previous Close 1.79
Open 1.79
Price To Book 2.65
Market Cap 27998786
Shares 15,072,559
Volume 34,609
Short Ratio
Av. Daily Volume 49,732

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data released January 2017. Patient enrollment to resume - noted August 2, 2018.
Oncoprex With Tarceva
Non-small cell lung cancer (NSCLC)

Latest News

  1. Genprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsWire
  2. NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.'s Transformative Work in Gene Therapy
  3. NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.’s Innovative Approach to Gene Therapy
  4. Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City
  5. NetworkNewsWire Announces Publication on Gene Therapy’s Promise for Improving Patient Treatments and Market Profitability
  6. 5 Biotech Stocks to Keep an Eye on in 2019
  7. Genprex Strengthens Senior Team and Continues to Advance Operations
  8. Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors
  9. Genprex to Present at NobleConXV in Fort Lauderdale, Florida
  10. Genprex to Present at Biotech Showcase™ 2019 in San Francisco
  11. Are Insiders Buying Genprex, Inc. (NASDAQ:GNPX) Stock?
  12. Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019
  13. Genprex to Present at the 11th Annual LD Micro Main Event
  14. Genprex Provides Clinical and Corporate Update for Third Quarter 2018
  15. Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations
  16. Genprex to Present at Upcoming Investor and Industry Conferences
  17. Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program
  18. Genprex to Present at Upcoming Investor Conferences
  19. Genprex Provides Clinical and Corporate Update for Second Quarter 2018
  20. Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung Cancer